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Abstract: The hepatitis C virus (HCV), a hepatotropic plus-strand RNA virus of the family 
Flaviviridae, encodes a set of 10 viral proteins. These viral factors act in concert with host 
proteins to mediate virus entry, and to coordinate RNA replication and virus production. 
Recent evidence has highlighted the complexity of HCV assembly, which not only 
involves viral structural proteins but also relies on host factors important for lipoprotein 
synthesis, and a number of viral assembly co-factors. The latter include the integral 
membrane protein p7, which oligomerizes and forms cation-selective pores. Based on these 
properties, p7 was included into the family of viroporins comprising viral proteins from 
multiple virus families which share the ability to manipulate membrane permeability for 
ions and to facilitate virus production. Although the precise mechanism as to how p7 and 
its ion channel function contributes to virus production is still elusive, recent structural and 
functional studies have revealed a number of intriguing new facets that should guide future 
efforts to dissect the role and function of p7 in the viral replication cycle. Moreover, a 
number of small molecules that inhibit production of HCV particles, presumably via 
interference with p7 function, have been reported. These compounds should not only be 
instrumental in increasing our understanding of p7 function, but may, in the future, merit 
further clinical development to ultimately optimize HCV-specific antiviral treatments. 
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1. Introduction 
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Currently about 130 
million individuals are persistently infected with HCV [1]. In the course of two to three decades, 
ongoing virus replication puts these patients at risk to develop liver cirrhosis and hepatocellular 
carcinoma [2]. In fact, HCV infection is the most frequent indication for liver transplantation [3]. HCV 
is an extraordinary variable positive strand RNA virus belonging to the genus Hepacivirus within the 
family Flaviviridae. Patient isolates are grouped into at least six major genotypes deviating from each 
in as much as 30% of the nucleotide sequence [4]. At present, neither a selective antiviral therapy nor a 
vaccine for HCV is available and the only current therapy, a combination of pegylated Interferon-α 
and Ribavirin, is associated with severe side effects and is efficacious in only 50% of patients infected 
with the most prevalent viral genotype 1 [5]. Clinical trials of novel enzyme inhibitors have revealed 
that drug-resistance mutations compromise the efficacy of these antiviral compounds in monotherapy [6]. 
Moreover, for many drugs in development, narrow genotype-specificity limit their utility for treatment 
of patients infected with varying viral strains. Therefore, novel substances with antiviral activity, 
different mode of action, and ideally cross-genotype efficacy, are urgently needed to implement highly 
active combination treatment regiments for control of virus replication and escape. 
The HCV genome of about 9.6 kb is composed of the 5´ non-translated region (NTR), an open 
reading frame encoding a large polyprotein, and the 3´ NTR [7] (Figure 1). 
A set of cellular and two viral proteases, NS2/3 and NS3/4A, liberate the individual viral proteins. 
The N-terminal portion of the polyprotein contains the structural proteins core, envelope glycoprotein 1 
and 2 (E1, E2) that constitute the virus particle. These proteins are cleaved from the polyprotein by the 
host cell signal peptidase [8,9]. In case of the core protein, an additional cleavage step mediated by the 
signal peptide peptidase liberates the mature C-terminus [10]. Further downstream the polyprotein 
harbors p7, a short integral membrane protein, and the non-structural (NS) proteins NS2, NS3, NS4A, 
NS4B, NS5A and NS5B. Proteins NS3 to 5B are the minimal viral components of the membrane-bound 
replication complexes which catalyze RNA replication [11,12]. 
For years, HCV researchers have struggled with the lack of adequate tissue culture systems 
sustaining virus replication and thus permitting molecular analyses of HCV replication. However, 
recent development of novel cell culture models, including subgenomic replicons [12], HCV 
pseudoparticles [13,14], and ultimately the JFH1-based infection system [15–17], has not only 
gradually removed this roadblock, but also lead to the accumulation of new insights into essential 
aspects of the HCV replication cycle [18]. With regard to assembly and release of infectious HCV 
particles, essential roles of viral and host factors have been defined. On one hand, cellular factors 
involved in the secretion of lipoproteins like the microsomal triglyceride transfer protein (MTP), 
apolipoprotein B and E (ApoB, ApoE), have been recognized as essential co-factors of HCV particle 
production [19–21]. On the other hand, it was realized that besides the canonical structural proteins 
core, E1 and E2, also other viral factors including NS5A, NS4B, NS3, NS2 and p7, play crucial, yet at 
present poorly understood, roles in the production of infectious viral progeny [22–26]. Viruses 2010, 2                  
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Figure 1. Schematic representation of the HCV genome, virus particle and membrane 
associated replication complex.  
 
Note: The virus particle is composed of the viral structural proteins core, envelope protein 1 and 2, 
as well as host cell lipoproteins. Whether additional viral proteins are incorporated (e.g., p7) is 
presently unknown. The minimal viral factors needed for establishment of functional replication 
complexes are the NS3 to NS5B proteins [12]. Viral proteins that have essential co-factor function 
during virus assembly are highlighted by red asterisks. 
 
These novel findings highlight the complexity of the HCV assembly process which is coordinated 
by multiple viral and host-derived factors and is tightly linked with the cellular lipoprotein secretion 
pathway. Understanding and dissecting the individual contributions of these factors will be a major 
challenge that will engage molecular virologists and cell biologists in the future. At the same time 
these studies are likely to reveal novel targets and modes for antiviral therapy. In this regard, the 
smallest among the viral assembly co-factors, p7, has recently attracted a lot of attention. Here we 
review current knowledge of p7 structure and function and highlight possible avenues for p7-based 
inhibition of HCV replication. 
2. Structure and Function of HCV P7 
2.1. P7 Topology and Structure 
The HCV p7 protein is a small, integral membrane protein of 63 amino acids that is encoded at the 
junction between the structural and non-structural region of the HCV polyprotein. Although most 
cleavages in the HCV polyprotein precursor proceed to completion during or immediately after 
translation, cleavages are delayed at the E2-p7 and p7-NS2 sites, leading to the production of an  Viruses 2010, 2                  
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E2-p7-NS2 precursor [27]. In addition, processing between E2 and p7 is incomplete resulting in the 
production of fully processed E2 and uncleaved E2-p7 [28,29]. 
When expressed on its own in mammalian cells, epitope tagged p7 has been shown to insert into ER 
membrane with two membrane-spanning helical domains, both its N- and C-termini exposed to the ER 
lumen, and a short hydrophilic loop facing the cytosol [30]. Alternatively, a protein topology where 
the C-terminus is orientated towards the cytoplasm may be possible [31]. The second transmembrane 
helix of p7 acts as a signal peptide to target NS2 to the ER, although when expressed by itself, NS2 is 
able to insert into membranes also independent of any p7 sequence [32]. 
Early electron microscopy studies suggested that p7 monomers assemble into hexamers [33], or 
heptamers [34] in artificial membranes. Computational modeling and secondary structure predictions 
were used to create structural models of monomeric and oligomeric p7 [30,35]. Recently, the   
three-dimensional structure of hexameric p7-complex was determined by single-particle electron 
microscopy at a 16 Å resolution [36]. Chemically synthesized full length p7 monomers were detergent 
solubilized, negatively stained, imaged using the random conical tilting approach and analyzed by 
single particle reconstruction. Using this approach, a hexameric complex with a flower-shaped 
architecture and six protruding petals oriented toward the ER-lumen was revealed [36] (Figure 2). This 
report of the entire p7-protein complex provides detailed molecular insights into p7 structure and 
function and will facilitate drug design in the future. Very recently a detailed structural analysis of 
monomeric p7 has been reported [37]. Using NMR and molecular dynamics simulation, Montserret  
et al. observed an unexpected N-terminal α-helix which is connected to the first transmembrane helix 
(TM1) via a short turn. In addition, a long cytosolic loop extending from residue 33 to 39, including 
the di-basic motif and connecting TM1 and TM2 was revealed [37]. Importantly, some of these 
observed structural elements, for instance the N-terminal α-helix or a longer cytosolic loop, differ from 
previous predictions of the secondary structure of p7 [37].  
Figure 2. Structure of monomeric and hexameric HCV p7. 
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Figure 2. Cont. 
 
Note: (A) Primary sequence of HCV-J p7 protein (genotype 1b) with color code as follows: Yellow, 
Ser, Thr, and Asn; green, Cys; cyan, His; blue, Arg and Lys; red, Glu; magenta, Trp; purple, Tyr; 
black, Pro; gray, any other residues. (B) Schematic representation of helical, turn, and loop regions 
deduced from the NMR structure [37] and (C, D) side view of the p7 representative monomer. 
Residues which are expected to point towards the ion channel are highlighted with boxes. (E) 
Single particle electron microscopy of the HCV p7 channel as recently reported by Luik et. al. [36]. 
A typical view from a raw image of p7 oligomers negatively stained with phosphotungstic acid at 
low magnification is given. (F) The authors fitted simulated p7 monomers into the hexameric 
volume of the structure derived by electron microscopy. C and N termini of the atomistic p7 model 
are oriented toward the petal tips. (A–D) are reprinted from [37] and (E), (F) from [36] with 
permission. 
 
2.2. P7—A Viroporin and True Ion Channel? 
In vitro, p7 forms oligomers and is capable of conducting ions across artificial membranes in a 
cation-selective manner [33,37–39]. Consistent with the structure of p7, electrophysiological studies 
indicate that the N-terminal helix of p7 is oriented towards the channel pore [40,41]. Due to the ability 
to sustain ion fluxes, p7 has been included into the expanding family of viral proteins known as 
viroporins. Viroporins are small, virus-encoded polypeptides that interact with membranes comprising 
at least one transmembrane segment. Moreover, oligomerization is an essential prerequisite for their 
ability to modify the membrane´s permeability to ions or other small molecules [42]. Typically, 
viroporins are small hydrophobic proteins comprised of about 60–120 amino acids that encode at least 
one transmembrane passage. The family includes viral proteins from diverse virus families including 6k of 
alphaviruses, M2 of influenza virus A, vpu of HIV-1 or picornavirus 2B. Generally, viroporins are not Viruses 2010, 2                  
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essential for RNA replication of the virus, but their presence promotes virus assembly/release and, in 
the case of the M2 protein, also virus entry. Interestingly, it was recently shown that the human 
polyoma JC virus, a non-enveloped DNA virus, also encodes a viroporin: The JC virus agnoprotein 
forms homo-oligomers, permeabilizes membranes and promotes virus release [43]. However, with the 
exception of influenza A virus M2 and HIV-1 vpu, little is known as to how these viral factors 
contribute to the release of infectious particles. Moreover, the rather broad definition of viroporins 
includes proteins which rather unspecifically permeabilize membranes and, at the same time, true ion 
channels with precise ion selectivity and intricate gating mechanism. Given these fundamental 
differences, it is likely that individual viroporin family members facilitate virus production by different 
mechanisms. Our mechanistic understanding of the role and function of a viroporin, and a direct link 
between its ability to conduct ions and its role in the virus life cycle, is probably most refined for the 
influenza A virus M2 protein. M2 is a proton-specific channel that is gated by pH [44,45]. Besides a 
crucial role of this protein during virus entry and uncoating, the proton channel function is important to 
prevent acidification of the trans-Golgi network thus avoiding premature conformational changes of 
influenza hemaglutinin in virus-producing cells [46]. 
Recent evidence suggests that the ion channel activity of HCV p7 (genotype 1b) is activated at 
acidic pH [47]. Furthermore, p7 was shown to substitute for M2 in facilitating the transport of the 
influenza HA protein to the cell surface in a cell-based assay [48]. Together these results imply that 
HCV p7 may operate in an M2-like fashion to facilitate HCV particle production. Both influenza A 
virus and HCV carry viral fusion proteins who’s fusion activities are triggered by conformational 
changes induced by low pH [14,49,50]. Therefore, dissipating the low pH of cellular secretory 
compartments may protect the HCV glycoproteins from premature induction of membrane fusion by 
low pH, thus facilitating production of infectious viral progeny. However, secreted HCV particles are 
resistant to low pH and, only after prolonged incubation of cell surface-bound particles at 37 °C, the 
virus acquires increased pH-responsiveness which then permits triggering of virus cell fusion [50]. 
This indicates that secreted HCV particles require certain additional stimuli like for instance receptor 
interactions to prepare the virus for low pH-induced fusion and infection. Although these findings 
make a role of p7 in protecting glycoproteins from low pH during assembly appear less likely, it is 
important to realize that such a function of p7 could also be crucial to allow proper folding of the 
glycoproteins. After all it is possible that immature glyocoprotein complexes or more generally viral 
assembly intermediates are susceptible to low pH-dependent misfolding. As a consequence, dissipation 
of low pH in the secretory compartments by p7 may be an essential prerequisite for production of 
infectious viral progeny. 
In case of Influenza virus M2, channel opening is induced by protonation of the so called   
“pH-sensor” histidine at position 37 at low pH [51]. Recently, a histidine of p7 at position 17 has been 
suggested to function in a homologous fashion [47,52]. However, this position is not fully conserved 
among p7 proteins from different HCV genotypes (Figure 2 and [53]). Moreover, mutation of this 
residue abrogated ion channel function of genotype 1b-derived p7 [47] while the same mutant in the 
context of a genotype 1a-derived p7 exhibited wild-type ion channel activity [40]. Recently, Meshkat 
et al. analyzed the relevance of p7’s HXXXY/W motif (position 17–21) by reverse genetics using the 
JFH1 infection system. However, mutation of His-17 slightly increased production of infectious 
particles [54] indicating that this amino acid is not absolutely essential for p7 function. Although these Viruses 2010, 2                  
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results cast some doubts on the relevance of His-17 as essential residue for gating of p7 ion 
channeling, the notion that HCV p7 may act as a proton channel that is crucial for virus assembly 
certainly remains an interesting hypothesis that warrants further analysis. The recent progress made in 
the structural analysis of p7 should facilitate and guide these experiments, thus ultimately increasing 
our understanding of the p7 ion channel. In fact, the recent NMR structure of a genotype 1b p7 
monomer (Figure 2) suggests that several hydrophobic residues protrude towards the channel lumen 
(e.g., V24 and F25) [37]. In the context of a p7 oligomer these residues may form two rings of 
hydrophobic side chains which could act as an energetic barrier limiting the permeability of the 
channel towards ions. Conformational changes of the monomers may move these residues apart, thus 
opening the channel for conductance of ions. Although more experimental work is necessary to 
confirm this hypothesis, the aforementioned rings of hydrophobic amino acids are reminiscent of those 
observed in channels like the nicotinic acetylcholine receptor [55], the MscL channel [56] and the 
bacterial K_channel [57] where rigid movements of helical channel segments permit channel opening 
and thus ion conductance. 
2.3. Subcellular Localization of P7  
A number of studies have investigated the subcellular localization of p7 in transfected cells as the 
partitioning of p7 to individual cellular compartments may provide important clues about its function. 
However, due to the paucity of useful p7-specific antibodies, mostly epitope-tagged p7 variants have 
been employed and localization studies of virus-producing cells with functional p7 are still lacking. 
Carrere-Kremer  et al. reported that ectopically expressed p7 mainly localized to the endoplasmic 
reticulum of HepG2 cells while a small percentage of the over-expressed p7 protein was detected at the 
plasma membrane [30]. Griffin et al. utilized p7-GFP or FLAG-p7 fusion constructs and observed  
co-localization of p7 with mitochondrial-associated ER and mitochondrial membranes in 293T   
cells [48]. This pattern was also seen when p7 was expressed in the context of other HCV structural 
proteins. In fact, epitope-labeling p7 at its C-terminus primarily revealed an endoplasmic reticulum 
distribution whereas labeling the N-terminus yielded mostly a mitochondria-like localization [58]. 
Given these findings, these authors suggested that separate pools of p7 resident in distinct cellular 
compartments and playing specific roles in the viral replication cycle may exist. With the development 
of an antibody to the C-terminus of genotype 1b-derived p7, an ER-like localization of native untagged 
p7, independent of the presence or absence of the upstream signal peptide, was confirmed in 
transfected 293T [58]. More recently, localization of epitope-tagged p7 proteins expressed in the 
context of replication competent JFH1-based full length genomes were reported [59]. This study 
confirmed that also enhanced green fluorescent protein (eGFP)- or a hemagglutinin (HA)-tagged p7 
localizes to the ER in transfected human hepatocarcinoma cells (Huh-7) [59]. However, unfortunately 
the GFP-tagged recombinant genome was not assembly-competent and the HA–tag in the JFH1 
genome reverted to the wild-type sequence. Since both tagged p7 variants did not sustain production of 
infectious particles, further studies are necessary to establish localization of functional p7 in virus 
producing cells. Nevertheless, the important findings summarized above are consistent with a model 
where p7 modulates the cellular secretory compartments, most notably the endoplasmic reticulum. As 
the luminal pH of the secretory pathway is a key determinant of post-translational modification, 
protein and lipid sorting (the interested reader is referred to [60]), it is conceivable that modification of Viruses 2010, 2                  
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luminal milieu may be important for virus production. Furthermore, the localization studies described 
above with over-expressed p7 constructs, suggest that p7 may also modify mitochondrial functions.  
2.4. Clues of P7 Function Based on Animal and Tissue Culture Experiments 
The first proof for an essential function of p7 came from animal experiments, which established that 
recombinant genomes encoding mutant p7 proteins did not initiate productive infection upon 
intrahepatic injection into chimpanzees [61]. Moreover, disruption of uncleaved E2-p7 or p7-NS2 by 
insertion of an encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) and 
mutations of the conserved di-basic motif within the cytoplasmic loop, abolished infectivity in this 
system. However, it was unclear how mechanistically p7 contributes to HCV infection. 
At this time, experiments with subgenomic HCV replicons (which do not encode p7) in tissue 
culture had already confirmed that p7 was dispensable for HCV RNA replication [12], thus indicating 
that p7 functions in life cycle steps that are not modeled with subgenomic replicons. When Bartosch 
and Hsu reported that infectious HCV pseudoparticles, i.e. retroviral particles carrying HCV 
glycoproteins in place of retroviral envelope proteins, are readily produced in 293T cells and infect 
human liver cells in envelope protein- and receptor-dependent fashion, it was clear that also key steps of 
viral entry occur independent of p7 [13,14]. Recent work applying the JFH1-based infection system has 
now firmly established that p7 is required for assembly and release of infectious HCV particles [53,62]. 
Transfection of virus genomes carrying partial or complete deletion of p7 or different point 
mutations reduced or ablated production of infectious particles [53,62]. These genetic studies also 
highlighted an important role of the fully conserved di-basic motif for p7 function which at the same 
time is also crucial for ion channeling in artificial membranes [48]. Of note, replacement of the   
di-basic motif in p7 (residues K33, R35) of the efficient genotype 2a chimera Jc1 by two glutamine 
residues (Q33, Q35) reduced not only production of total infectivity by ca. 100-fold. At the same time 
this mutation also profoundly changed the ratio between cell-associated infectious particles (which are 
released upon rupturing the cells by consecutive cycles of freeze and thaw) and released particles [53]. 
These results suggest that p7 is not only important for assembly, but also for efficient release of 
infectious progeny from cells. The specific infectivity of these particles (i.e. the infectivity per given 
number of physical particles), however, was not reduced compared to wildtype particles. This 
observation provides some indirect evidence supporting the notion that p7 is dispensable for virus 
entry, since if p7 was important during entry, it is unlikely that particles produced with partially 
defective p7 are as infectious as wild-type HCV [53]. Further clarification of this issue awaits the 
precise proteomic analysis of HCV particles which should answer the question if p7 is incorporated 
into mature viral particles and in turn modulates their properties. It is worth mentioning here that the 
p7 protein of bovine viral diarrhea virus (BVDV), a relative of HCV from the genus pestivirus of the 
family flaviviridae, is also essential for the production of infectious particles [63]. However, BVDV p7 
was not found in secreted virus particles, suggesting that BVDV does not package p7 into mature 
virions [64].  
Tissue culture experiments have revealed additional features of p7 that should help to understand its 
function and mode of action: First, recent evidence indicates that p7 is absolutely essential for 
production of infectious HCV particles [53,65]. This feature separates p7 from other viroporins, which Viruses 2010, 2                  
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only facilitate assembly and release of infectious progeny, and may be a reflection of a unique mode of 
action. At first, however, it was unclear if solely defective p7 was responsible for ablation of virus 
production or if alternatively aberrant polyprotein processing caused by mutation of p7 was 
accountable as well. P7 harbors a signal sequence for insertion of NS2 into the ER lumen and 
processing of the E2-p7 and p7-NS2 signal peptidase cleavage sites is precisely regulated by E2, NS2 
and notably also p7 sequences adjacent to the cleavage sites [30,66]. In fact, some p7 mutations like 
exchange of the di-basic motif for hydrophobic alanine residues, or deletion of p7 in the polyprotein, 
have a substantial impact on polyprotein processing, thus complicating interpretation of these data. 
Using a trans-complementation system where p7-defective full length genomes are rescued by HCV 
replicons expressing p7 in trans, Brohm et al. recently resolved this issue [65]. Although partial 
deletion of p7 in the polyprotein slightly changes polyprotein processing, virus production of this 
construct was restored when only p7 was expressed from helper replicon in trans. This finding not 
only firmly established the essential role of p7 for virus production, it also now provides a simple 
model to further investigate p7 function in the absence of secondary effects on polyprotein processing. 
Second, p7 function cannot be replaced by viroporins from other viruses. At least the two viroporins 
analyzed so far, influenza A virus M2 and HIV-1 vpu, were unable to rescue assembly of p7-defective 
full length genomes [65], arguing that p7 exerts an HCV-specific function. 
Third, a number of genetic evidences now strongly suggest that p7 acts in concert with additional 
viral factors, which may in part explain, why M2 and vpu are unable to compensate for p7: Haqshenas 
et al. reported that an inter-genotypic JFH1 chimera with GT1b p7 was viable yet attenuated when 
compared to JFH1 [41]. In addition, the highly efficient J6CF p7 variant (GT2a) boosted virus 
production in the context of the homologous GT2a strain JFH1, but almost abrogated accumulation of 
infectious virions in the environment of the more distantly related GT 1b virus Con1/C3 [53]. On one 
hand, these data strongly suggest that p7 promotes virus particle production in a context-dependent and 
genotype-specific manner, most likely due to interactions with other viral factors. On the other hand, 
these results also suggest that p7 variants from divergent patient isolates (e.g., GT2a JFH1 and J6CF) 
differ with regard to their ability to sustain virus production suggesting that p7 modulates viral fitness. 
In agreement with this interpretation, using the trans-complementation system Brohm et al. provided 
evidence that a tyrosine residue close to the conserved di-basic motif of p7 is important for optimal 
virus production in the context of genotype 2a viruses [65]. 
Which viral factors, however, p7 cooperates with, is currently poorly defined. Nevertheless, first 
genetic evidence suggests that p7 may function in concert with NS2 or core: Yi et al. observed that an 
inter-genotypic virus chimera comprising H77 and JFH1 segments (GT1a-2a) fused at a position 
within NS2 acquired compensatory mutations residing in p7 and NS2 [26]. Moreover, when we 
mapped the optimal junction for Con1-JFH1 chimeras (GT1b-2a), a crossover downstream of the first 
TM-helix of NS2 was superior to a junction at the C-terminus of p7 [67]. Finally, core protein 
mutations lethal for virus assembly can be rescued by compensatory mutations within p7 [68]. 
Together these findings provide an important framework guiding further studies geared to reveal the 
mechanisms of p7 function. Notably, the discovery that vpu counteracts an interferon stimulated 
restriction factor (tetherin) that prevents release of infectious human immunodeficiency virus 1   
(HIV-1), compared to the function of M2 described above, illustrates the diversity of mechanisms by 
which viroporins facilitate virus propagation. Viruses 2010, 2                  
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3. P7-Based Antiviral Strategies 
In theory, each step of the virus replication cycle and each cellular or viral factor involved in any of 
these steps is a possible drug target. The recent findings that p7 is essential for virus production 
combined with the knowledge that successful intervention with viral ion channel function is feasible, 
has nourished hopes that p7-based antiviral strategies can be implemented. Such strategies may rely on 
prevention of p7 oligomerization, its interaction with viral or host factors, or possibly blockage of the 
channel pore by small molecules. Although, robust in vitro assays for screening p7 inhibitors at high 
throughput level are still lacking, also whole life cycle screening systems may prove useful to identify 
molecules that interfere with p7 function. Several p7 inhibitors with at least confirmed antiviral 
activity in cell culture, and which primarily emerged from studies performed with viroporins from 
other viruses, have already been reported. These include amantadine, which inhibits the M2 channel of 
the influenza A virus [69–71], hexamethylene amiloride (HMA), an inhibitor of the HIV-1 vpu ion 
channel [72] and long-alkyl-chain iminosugar derivatives [38]. 
3.1. Amantadine 
Amantadine is an organic compound also known as 1-aminoadamantane and inhibits the cell entry 
of influenza A viruses by interacting with the viroporin M2. It has proven efficacious in preventing 
influenza A virus infections although rapid emerge of drug-resistant variants have been reported. In 
fact utilization of amantadine and its derivative rimantadine for prophylaxis and treatment is no longer 
recommended in the USA due to high prevalence of drug-resistant virus (http://www.cdc.gov/ 
flu/han011406.htm). Using solid-state NMR spectroscopy recently, two amantadine binding sites 
within the M2 ion channel were defined in the presence of phospholipid bilayers [73]. The   
high-affinity site, occupied by a single amantadine molecule, is located in the N-terminal channel 
lumen whereas a low-affinity binding site was observed on the C-terminal protein surface. 
In 1997, Smith reported that amantadine treatment was effective in inducing sustained biochemical 
and virological response in patients with chronic hepatitis C who had previously failed to respond to 
interferon monotherapy [74]. However, other clinical studies failed to confirm a beneficial effect of 
monotherapy or combination treatment with IFN-α/ribavirin [75,76]. Further hopes that amantadine 
may inhibit HCV were fueled by the observation that amantadine prevents p7 ion channel activity in 
artificial membranes [33] and in a cell-based hemadsorption surrogate assay [48]. Leucine residues 51 
through 57 of p7 were reported to be involved in a p7-amantadine interaction [77] and mutation of this 
leucine-rich region conveyed resistance of p7 to amantadine in a liposome-based ion channel activity 
assay [52]. However, using p7 peptides inserted into planar lipid bilayers, we observed inhibition of p7 
ion channel activity only at high amantadine concentration [78]. Each study applied different p7 
constructs with respect to peptide production, isolate/genotype, modification or mutation and different 
assay setups (planar lipid bilayers or liposome dye release) which might explain the discrepancies in 
amantadine inhibition. 
In the HCV cell culture system amantadine at a dose of 50 µM did not affect RNA replication, 
particle production and infectivity of JFH1 and several JFH1-derived chimeras [78]. At higher 
concentrations a moderate inhibition of production of infectious HCV could be detected for some chimeric 
genomes suggesting a genotype-dependent inhibition by amantadine [79]. This genotype-dependent Viruses 2010, 2                  
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sensitivity has also been observed in p7 ion channel activity assays [79]. For example, JFH1-derived p7 is 
not blocked in a liposome-based ion channel assay and infectious particle production, whereas a genotype 
3a p7 was susceptible to inhibition by amantadine in both systems. In addition, Griffin et al. found that 
inhibition profiles of p7 inhibitors in cell culture did not always reflect the profiles of different p7 ion 
channels activities in vitro [79]. Despite these partly discrepant findings, it is clear that the inhibition 
of HCV by amantadine is, at best, moderate. Moreover, the mostly disappointing results of clinical 
studies using amantadine in HCV infected patients do not support clinical use of this drug for HCV 
treatment. Nevertheless, amantadine may be a useful tool to study HCV assembly and p7 function in 
vitro. 
3.2. Amilorides 
Amiloride is a guanidinium group containing pyrazine derivative used in the management of 
hypertension and congestive heart failure. Similar to p7 the HIV-1 vpu-protein forms cation-selective 
ion channels in vitro and enhances the budding and release of virus particles [80]. In 2002, Ewart et al. 
demonstrated that amiloride derivatives block ion channel activity and enhancement of virus-like 
particle budding caused by HIV-1 vpu [72]. Modeling the binding of the amiloride derivative to vpu 
revealed that the inhibitor orientates along the channel axis with its alkyl ring pointed inside the pore 
and the hydrophilic serine-23 residue might be a favorable binding site [81]. Recently, p7 ion channel 
activity was also shown to be inhibited by hexamethylene amiloride [39]. In cell culture, however, 
cellular toxicity at drug concentrations required to achieve p7 inhibiton preclude a clear conclusion 
about the inhibitory effect of amilorides on HCV particle production in tissue culture [79]. To our 
knowledge clinical development of amilorides for HCV treatment is currently not pursued. 
3.3. Iminosugar Derivatives 
Iminosugars are monosaccharide mimics with the ring oxygen replaced by a nitrogen atom. They 
occur naturally in certain plants and microorganisms and cannot be metabolized by hydrolytic 
enzymes and the nitrogen lends itself well to adding various alkyl sidechains, which influence the 
compounds’ pharmacokinetic and toxicologic profiles [82], It was previously shown, applying the 
HCV surrogate model bovine diarrhea virus (BVDV) that glucose-derivatives deoxynojirimycin 
(DNJ)-containing iminosugars, such as N-butyl-DNJ (NB-DNJ) and N-nonyl-DNJ (NN-DNJ), are 
potent antivirals inhibiting ER α-glucosidases I and II [83]. These enzymes remove glucose residues 
from the high-mannose N-linked glycans attached to nascent glycoproteins and this processing step is 
essential for the subsequent interaction between the glycoproteins and ER chaperones calnexin and 
calreticulin [84]. Therefore, inhibition of α-glucosidases may interfere with proper folding and 
maturation of viral envelope glycoproteins and, consequently interfere with production of infectious 
particles. Importantly, long alkyl chain derivatives such as NN-DNJ and also the galactose-based   
NN-DGJ, a derivative of NN-DNJ which, due to its galactose-backbone, does not bind and interfere 
with alpha-glucosidases, also inhibit HCV p7 ion channel activity in vitro, whereas the short alkyl 
chain derivatives (NB-DGJ,  NB-DNJ) are inactive in this assay [38]. Similar to data that have   
been described for BVDV, no effect of NN-DNJ and NN-DGJ on HCV RNA replication was   
observed [78,79]. Furthermore, none of the inhibitors affected viral protein synthesis and processing of Viruses 2010, 2                  
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the polyprotein precursor, corroborating the lack of cytotoxicity at the chosen concentrations. 
However, a dose-dependent reduction in the amount of infectious viruses of genotype 2a and 1b could 
be demonstrated [78,79]. Furthermore, a high dose of NN-DNJ successfully cleared HCV from cell 
cultures in the course of several consecutive cell culture passages [78]. This substantial antiviral effect 
may be attributable to the long alkyl side chain that confers an HCV p7 inhibitory effect. Thus, 
compounds combining a DNJ headgroup with a long alkyl side chain, such as NN-DNJ, may have two 
mechanisms of action: inhibition of ER-resident α-glucosidases and blockade of p7 ion channel 
activity. A derivative of NN-DNJ (UT-231B) has been administered in a clinical phase II study to 
previous non-responders to IFN-α-based therapy but has not proven significant antiviral efficacy [85]. 
In conclusion, iminosugar derivatives efficiently inhibited p7 ion channel activity in vitro and 
suppressed spread of HCV in cell culture making them attractive compounds for further investigations 
especially with respect to the mode of action. 
3.4. BIT225 
A recent study by the company Biotron identified a novel small molecule, termed BIT225, which 
represents a new class of p7 ion channel inhibitor [86]. BIT225, a substituted napthoyl guanidine, was 
identified after screening a compound library in a semi-quantitative, moderate throughput p7-based 
bacterial assay. The compound has a mid nanomolar IC50 against BVDV and shows antiviral synergy 
with IFN-α, ribavirin and NS5B polymerase inhibitors. Furthermore, BIT225 was able to inhibit p7 ion 
channel function in planar lipid bilayers and has successfully completed a phase Ia dose escalating, 
single dose safety trial, in healthy volunteers and a phase Ib/IIa trial to evaluate the safety and 
pharmacokinetics of repeated dosing for selected doses of BIT225 in HCV-infected persons.   
A modest, but statistically significant drop in patient’s viral load was detected over seven days of 
dosing [86]. The effect of BIT225 in the HCV cell culture system has not yet been described. 
4. Conclusion and Outlook 
The recent development and application of HCV cell culture systems has firmly established that p7 
is essential for production of infectious virus progeny. In parallel, in vitro studies using artificial 
membranes have highlighted the ability of p7 to oligomerize and to conduct ions in a cation-selective 
fashion. However, the conceptual, mechanistic and experimental link, as to how the p7 ion channel 
function contributes to production of infectious particles, is still incomplete. Certainly, manipulation of 
the pH of the cellular secretory compartment by p7 may facilitate maturation, folding and transport, of 
essential viral assembly factors and thus contribute to production of infectious particles. While in this 
model p7 is an “M2-like” protein, evidence for proton channel activity in artificial membranes or, 
more importantly, within virus producing cells has not been provided. At least the localization of p7 
primarily at the ER is in principle compatible with this model. At this point, however, alternative 
models cannot be dismissed. The recent finding that vpu facilitates release of HIV-1 particles by 
interfering with tetherin, is just one example that illustrates the diversity of possible mechanisms. In 
this case, it is unclear if and how vpu-dependent changes of membrane permeability contribute to 
interference with tetherin. Viruses 2010, 2                  
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Further dissection of specific, and possibly unique, properties of p7 is likely to define how this 
protein operates in the course of HCV assembly. The findings that p7 acts in an isolate-specific 
fashion, possibly by interacting with other viral factors, and the observation that p7 from different viral 
strains sustain virus production with divergent efficiency, are important leads that may be translated 
into mechanistic insights in the future. Certainly, identification of viral and host proteins that interact 
with p7 should help to characterize its mode of action. Moreover, finding answers to the question how 
p7 conducts ions, which ions are transported, and at which location within cells p7 modulates the ion 
milieu, will be critical. At present, the relevance of p7 ion channel function for virus production is 
mainly based on intriguing correlations: mutations that abrogate ion channeling in artificial 
membranes also interfere with production of infectious particles. In addition some small molecules that 
ablate channeling in vitro have been shown to moderately reduce virus production. However, direct 
proof that these molecules specifically act via p7, thus preventing virus production, is still elusive. For 
M2 of influenza A, mutations conferring resistance to amantadine map to M2. In addition, these 
mutations confer resistance of the virus to amantadine and at the same time to the M2 ion channel in 
cell based channel assays. In that very same sense the emerging novel compounds which presumably 
inhibit p7 may be instrumental to firmly establish the relevance of its ion channel function. In the long 
run, some of these molecules characterized by basic science at the laboratory bench, may progress to 
the bedside, thus expanding therapeutic options for treatment of hepatitis C.  
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